NRAS Recombinant monoclonal antibody

NRAS, also named as N-ras and NRAS1, is neuroblastoma RAS viral (v-ras) oncogene homolog from the mammalian ras gene family and it is a member of the small GTPase superfamily. RAS proteins are involved in signal transduction pathways, and bind GDP/GTP and possess intrinsic GTPase activity. It is mapped on chromosome 1, and it is activated in HL60, a promyelocytic leukemia line. Defects in NRAS are a cause of juvenile myelomonocytic leukemia (JMML). NRAS is one member of RAS gene family of oncoproteins, which is commonly mutated in melanoma and hematopoietic cancers via mapped on chromosome 1 (PMID: 2327491, PMID: 26990546). NRAS mediates activation of both mitogen-activated protein kinase (MAPK) and PI3K/AKT/MYC signaling (PMID: 17297468). NRAS induced classical MAPK signaling leads to cyclin D1 expression and cell cycle dysregulation and promotion of prosurvival pathways (PMID:7970723,PMID: 18246127). In addition, NRAS effectively prevents Glycogen Synthase Kinase3 (GSK3)-mediated phosphorylation of MYC via PI3K/AKT, which results in enhanced activity of endogenous MYC protein (PMID: 17297468). Mutational NRAS causes Ras-GTP to be in a state of continuous activation, which results in malignant proliferation and metastasis (PMID: 24985059).